Therapeutic Antibodies - Ultimately

Twelve of the top-20 medicines are projected to be antibodies by 2024 (Evaluate Pharma, 2019) and sales could top $400B by 2030 (Fatpos Global, March 2021). Approximately 85% of approved antibodies were generated using in vivo discovery tools (Antibody Society, October 2020). Therapeutic antibodies in clinical development are increasingly derived from transgenic platforms.

Abvivo creates high-performance antibodies against targets with high human-rodent and intra-protein family homology and other challenges using industry-leading transgenic and B cell cloning technologies. Partners avoid freedom-to-operate risk and the primary discovery steps, yet obtain best-in-class antibody development candidates. Ultimately target-solving antibodies.

Abvivo designs and develops antibodies exclusively where the biopharmaceutical industry has the greatest proven needs. Flexible options include options, licenses and asset purchases. Abvivo does not disclose its programs or partners publicly. Ultimately business-promoting antibodies.

Contact for the industry's most cost-efficient path to human therapeutic antibodies.